> Comparison of stochastic and deterministic models for gambiense sleeping sickness at different spatial scales: A health area analysis in the DRC

Christopher N Davis^{1,2,3*}, Ronald E Crump^{1,3}, Samuel A Sutherland^{1,4}, Simon E F $Spencer^{1,5}, Alice Corbella^{1,5}, Shampa Chansy⁶, Junior Lebuki⁶, Erick Mwamba Miaka⁶,$ Kat S Rock^{1,3}

1 Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research, The University of Warwick, Coventry, U.K.

2 School of Life Sciences, The University of Warwick, Coventry, U.K.

3 Mathematics Institute, The University of Warwick, Coventry, U.K.

4 Warwick Medical School, The University of Warwick, Coventry, U.K.

5 Department of Statistics, The University of Warwick, Coventry, U.K.

6 Programme National de Lutte contre la Trypanosomiase Humaine Africaine (PNLTHA), Kinshasa, D.R.C.

* C.Davis.7@warwick.ac.uk

Abstract

The intensification of intervention activities against the fatal vector-borne disease gambiense human African trypanosomiasis (gHAT, sleeping sickness) in the last two decades has led to a large decline in the number of annually reported cases. However, while we move closer to achieving the ambitious target of elimination of transmission (EoT) to humans, pockets of infection remain, and it becomes increasingly important to quantitatively assess if different regions are on track for elimination, and where intervention efforts should be focused.

We present a previously developed stochastic mathematical model for gHAT in the Democratic Republic of Congo (DRC), and show that this same formulation is able to capture the dynamics of gHAT observed at the health area level (approximately 10,000 people). This analysis was the first time any stochastic gHAT model has been fitted directly to case data, and allows us to better quantify the uncertainty in our results. The analysis focuses on utilising a particle filter Markov chain Monte Carlo (MCMC) methodology to fit the model to the data from 16 health areas of Mosango health zone in Kwilu province as a case study.

The spatial heterogeneity in cases is reflected in modelling results, where we predict that under the current intervention strategies, the health area of Kinzamba II, which has approximately one third of the health zone's cases, will have the latest expected year for EoT. We find that fitting the analogous deterministic version of the gHAT model using MCMC has substantially faster computation times than fitting the stochastic model using pMCMC, but produces virtually indistinguishable posterior parameterisation. This suggests that expanding health area fitting, to cover more of the DRC, should be done with deterministic fits for efficiency, but with stochastic projections used to capture both the parameter and stochastic variation in case reporting and elimination year estimations.

Author summary

Gambiense human African trypanosomiasis (gHAT, sleeping sickness) is a parasitic infection transmitted by tsetse in sub-Saharan Africa. The distribution of infections is patchy and highly correlated to the regions where humans and tsetse interact. This presents the need for mathematical models trained to the particular regions where cases occur.

We show how a stochastic model for gHAT, which captures chance events particularly prominent in small populations or with extremely low infection levels, can be directly calibrated to data from health areas of the Democratic Republic of Congo (DRC) (regions of approximately 10,000 people). This stochastic model fitting approach allows us to understand drivers of transmission in different health areas and subsequently model targeted control interventions within these different health areas.

Results for the health areas within the Mosango health zone show that this modelling approach corresponds to results for larger scale modelling, but provides greater detail in the locations where cases occur. By better reflecting the real-world situation in the model, we aim to achieve improved recommendations in how and where to focus efforts and achieve elimination of gHAT transmission.

Introduction

Mathematical models have an important role in the ability to quantify progress towards 2 or achievement of location elimination of transmission (EoT) of *gambiense* human African trypanosomiasis (gHAT) [\[1\]](#page-23-0). Cases of gHAT – a parasitic infection with a high probability of severe disease and death if left untreated $-$ have greatly declined in the last two decades, predominantly due to ongoing detection and treatment activities in the endemic regions $[2,3]$. However, when the target is EoT, it becomes key to estimate the real number of infections, which cannot directly be observed, to understand where transmission is still on-going and hence where continued intervention efforts are most ⁹ crucial $|4|$. It is thus necessary to develop fine-scale models, such that the spatial $\frac{10}{10}$ distribution of infections can be estimated across the endemic regions.

The current spatial distribution of gHAT cases is highly dependent on several 12 geographic factors, such as the density of the disease vector – tsetse (Glossina spp.) – $\frac{13}{2}$ suitability for the parasite, *Trypanosoma brucei gambiense*, and the location of human $_{14}$ settlements and places of work [\[5\]](#page-23-4). These factors mean the distribution of $gHAT$ 15 endemic regions is highly heterogeneous and confined to geographically distinct regions ¹⁶ or "foci", with very few cases detected in areas in between. These foci are typically ¹⁷ located in riverine areas of sub-Saharan Africa, where humans and tsetse come into contact $[6]$. As well as these environmental factors, local availability of $gHAT$ diagnostics and treatment will also impact the spatial infection distribution. There are ₂₀ long timescales of gHAT infection, which have been estimated at approximately three $\frac{21}{21}$ years before the likely death in the absence of treatment $[7]$. This means that early $\frac{22}{2}$ diagnosis can substantially reduce the likelihood of onward transmission, by reducing $\frac{23}{2}$ the time people spend infectious and hence the possibility that tsetse will take blood $_{24}$ meals on infected people, as well as preventing the worst disease and death in patients. ²⁵ Reductions in the time people spend as infectious, reduce the possibility that tsetse will $_{26}$ take blood meals on infected people and cause future transmission [\[8\]](#page-23-7). 27

Current gHAT control strategies focus on active and passive screening [\[9\]](#page-23-8). Active $\frac{28}{28}$ screening is the use of mobile teams to conduct mass screening of at-risk populations $\frac{29}{29}$ using serological tests, which detect the presence of antibodies to *Trypanosoma brucei* $\frac{1}{300}$

> gambiense. Positive serological tests are followed up with microscopy for parasitological $\frac{31}{21}$ confirmation, before treatment is provided. The current treatment options for gHAT are $\frac{32}{2}$ not recommended for treatment of non-confirmed individuals $[10, 11]$ $[10, 11]$. Passive screening $\frac{33}{2}$ is where gHAT cases are detected through self-referral to fixed health facilities and ³⁴ relies on training health staff and availability of diagnostic screening tests to be able to $\frac{35}{10}$ make diagnoses and administer treatment. Additional interventions such as vector $\frac{36}{100}$ control have also been deployed in selected high-prevalence locations to reduce tsetse $\frac{37}{20}$ populations and hence reduce transmission $[12]$, although operational considerations $\overline{}$ have prevented use of vector control in many endemic foci, especially in the Democratic ³⁹ Republic of Congo (DRC) which is a large country with most ($>57\%$) of the gHAT case burden for 2021 [\[2\]](#page-23-1).

> The fact that gHAT cases are spatially localised and the interventions to reduce case numbers are implemented in specific locations means that there are great benefits to $\frac{43}{45}$ modelling gHAT at small spatial scales. Several previous studies have only modelled $\frac{44}{40}$ gHAT infections in moderate to large populations. For example, health zones of around ⁴⁵ 150,000 people in the DRC [\[8,](#page-23-7) [13](#page-24-2)[–16\]](#page-24-3), former provinces of the DRC with more than ⁴⁶ 8,000,000 people [\[17\]](#page-24-4), foci in Guinea of 14,500 people [\[18\]](#page-24-5), Chad foci of 40,000 ⁴⁷ people $[19, 20]$ $[19, 20]$ and foci in Côte d'Ivoire of approximately 300,000 people $[21]$. These \qquad studies fit deterministic models to longitudinal case data, but due to the large ⁴⁹ populations, there can be large spatial variation within these regions. Some studies have \sim considered modelling individual villages $[22, 23]$ $[22, 23]$, but it is infeasible, both $\frac{51}{10}$ computationally and statistically, to fully fit complex models for all separate endemic $\frac{52}{2}$ villages in a country as large as the DRC.

> Here, we consider modelling gHAT infection for DRC health areas (regions of ⁵⁴ approximately 10,000 people). This is small enough to capture local variation in $\frac{55}{55}$ transmission and to define operationally-appropriate intervention areas, yet not so small so as to be too computationally intensive to implement across the endemic region, or mean $\frac{57}{100}$ there is insufficient data for each location to fit a model. The relatively small $\frac{58}{58}$ population sizes coupled with expected gHAT prevalence of $\langle 1\%$ meant we choose to $\frac{59}{2}$ use a stochastic model to capture the full range of possible model outcomes and $\frac{60}{60}$ uncertainty, since the stochastic effects will be relatively larger compared to larger 61 spatial scale studies $[24]$. A second advantage of stochastic modelling is that it is \sim straightforward to establish at what time in the simulation that elimination of 63 transmission and elimination of infection are achieved, whereas the analogous 64 deterministic model would require us to specific a proxy threshold for elimination $[25]$ – ϵ this is most pertinent to our projections forward in time following model calibration. ⁶⁶

> In this manuscript, we use the example health zone of Mosango in Kwliu province, σ DRC, to fit a stochastic model of gHAT infection to its 16 constituent health areas. $\frac{68}{100}$ This methodology updates the work of Crump et al. [\[8\]](#page-23-7) and combines tools from 69 Spencer [\[26\]](#page-25-3), with a particle Markov chain Monte Carlo (pMCMC) fitting $\frac{70}{20}$ procedure [\[27\]](#page-25-4) to allow for calibration of a stochastic transmission model, rather than $\frac{71}{100}$ relying fitting a deterministic variant without stochastic, event-driven variation.

> We assess the quality of model fitting for health areas and compare the benefits of $\frac{73}{2}$ directly fitting the stochastic model, to using a deterministic model, or the outputs from $\frac{74}{4}$ a stochastic model with posterior parameterisation derived from deterministic fitting. $\frac{75}{20}$ We also compare fitting the model to health zone data with the aggregation of model $\frac{1}{16}$ fitting for constituent health areas. While the fitting methodology is updated, we ensure π the process remains robust, automated, and replicable, such that multiple stochastic $\frac{1}{8}$ health area models can be fitted simultaneously. We propose a computationally efficient $\frac{79}{20}$ method to fit health area models for all analysable health areas in the DRC. $\frac{80}{20}$

Materials and methods 81

Ethics Approval was granted by the University of Warwick Biomedical and Scientific $\frac{1}{2}$ Research Ethics Committee (application number BSREC $80/21-22$) to use the $\frac{83}{2}$ previously collected DRC country HAT data, provided through the framework of the ⁸⁴ WHO HAT Atlas $[3]$, in this secondary modelling analysis. No new data collection took \bullet place within the scope of this modelling study. Full model code can be found at $\frac{86}{100}$ <http://doi.org/10.17605/osf.io/6rfwm>. 87

\mathbf{Data} and \mathbf{Data}

The World Health Organization (WHO) HAT Atlas data is a record of the globally $\frac{89}{89}$ reported gHAT cases across $[2, 3, 28]$ $[2, 3, 28]$ $[2, 3, 28]$. For the present study we have used the data in \Box the HAT Atlas from the DRC, which includes the location of each case, the year of $\frac{91}{91}$ detection, and the mode of detection (either active or passive screening). Where active $\frac{92}{2}$ screening for gHAT has occurred, the total number of people that were screened is $\frac{93}{2}$ given, along with a population estimate for the whole settlement. We used available ⁹⁴ $data for the time period of $2000-2020$.$

Using the geolocations (latitude and longitude coordinates) of active screening $\frac{96}{96}$ events or passive detections, we assigned the cases to administrative regions. This $\frac{97}{97}$ includes both health zones (typically about $150,000$ people) and health areas (sub-units $\frac{98}{98}$ of the health zones, typically about 10,000 people). For this process we used shape files ⁹⁹ provided by Nicole Hoff and Cyrus Sinai under a CC-BY licence (current versions can ¹⁰⁰ be found at <https://data.humdata.org/dataset/drc-health-data>) that define the 101 borders between neighbouring health areas. For entries missing geolocations we used the 102 names of villages and health areas to extract the HAT Atlas data, following a similar $_{103}$ algorithm to that presented by Crump et al. $[8]$. Details of the standardised process of $_{104}$ translating the HAT Atlas data to our extracted data set of cases by health area, year 105 and screening type for the present study is provided in $S1$ Text. 106

In this study, we focus on data for the health zone of Mosango (Fig [1\)](#page-4-0). We chose 107 this health zone as a case study since it is located in the relatively high-burden province $\frac{108}{108}$ of Kwilu, has had annual active screening for gHAT infection and the number of cases ¹⁰⁹ detected are geographically diverse, but some cases have been detected in each of the 110 health areas within the health zone. This allows us to compare results of previously $\frac{1}{111}$ fitting the health zone to the aggregated results of fitting its constituent health areas 112 here. All health areas have sufficient data to perform a model fit (see [S1 Text\)](#page-22-0).

Fig 1. Data for Mosango health areas.

A map of the location of Mosango, in the Kwilu province and Bandundu Sud coordination of the DRC (coordinations are the large geographic units, similar to provinces, for the organisation of gHAT activities). The map is divided into health area units, where possible, and health zone units otherwise. The Kwilu province is shown by the thick black border, the Bandundu coordination is shown in green and Mosango is dark green. Shown in smaller maps to the right are the distribution of the population (data provided by UCLA), the number of people screened (2000–2020) and the number of active and passive cases (2000–2020) across the health areas of Mosango (extracted from the WHO HAT Atlas [\[3\]](#page-23-2)). The largest number of active and passive cases is 220 and 208 respectively, both in the health area of Kinzamba II. Shape files used to produce these maps were provided by Nicole Hoff and Cyrus Sinai under a CC-BY licence (current versions can be found at <https://data.humdata.org/dataset/drc-health-data>).

\bf{Model} and the set of the set of

Here we describe the previously developed stochastic model (and its analogous 115 deterministic version) and detail the approach we took to perform fitting of this 116 stochastic model to longitudinal data for the first time.

$\bf{Compartmental\ gHAT\ model}$

We used a previously developed, compartmental, mechanistic model to represent 119 transmission of the T. b. gambiense between humans and tsetse, as transitions of people $_{120}$ and tsetse between infection states (see Fig 2 for an illustration of the latest version 121 published by Crump et al. [\[8\]](#page-23-7)). A susceptible person (S_H_i) can be bitten by an infected 122 tsetse to become exposed (E_{H_i}) before developing stage 1 (I_{1H_i}) and subsequently stage 123 $2 (I_{2Hi})$ gHAT infection, if not detected in screening before progression. Treated and 124 recovering people are represented by R_{Hi} . Infected people that are not treated are 125 assumed to die and, in the model, are replaced by a new susceptible person, such that $_{126}$ we have a closed population. We also include natural births and deaths in all classes. $_{127}$

Subscripts $i \in \{1,4\}$ denote two distinct human risk/behaviour groups in this model, 128 presented as "Model 4" in previous publications $[4, 8, 13, 14, 17, 19, 29, 30]$ $[4, 8, 13, 14, 17, 19, 29, 30]$ $[4, 8, 13, 14, 17, 19, 29, 30]$ $[4, 8, 13, 14, 17, 19, 29, 30]$ $[4, 8, 13, 14, 17, 19, 29, 30]$ $[4, 8, 13, 14, 17, 19, 29, 30]$ $[4, 8, 13, 14, 17, 19, 29, 30]$ $[4, 8, 13, 14, 17, 19, 29, 30]$. We assume a 129 majority of low-risk people $(i = 1)$ that may participate in active screening, and a 130 minority of high-risk people $(i = 4)$ that both have a larger chance of being infected by $\frac{131}{131}$ tsetse and do not participate in active screening. In this study, we do not consider 132 $i = 2, 3$ however we retain the same notation $(i = 1, 4)$ to align with other studies which 133 explore additional risk and behaviour groupings $[13, 19, 20]$ $[13, 19, 20]$ $[13, 19, 20]$.

The proportion of tsetse bites taken on low-risk and high-risk humans $(f_1 \text{ and } f_4 \text{ is }$ respectively) depend on both the relative availability and the relative abundance of the ¹³⁶ two risk groups. High-risk humans are assumed to be r times more likely to receive bites. $_{137}$ Therefore, $f_1 = \frac{k_1}{k_1 + k_2}$ $\frac{k_1}{k_1 + rk_4}$ and $f_4 = \frac{rk_4}{k_1 + r_4}$ $\frac{m_4}{k_1 + rk_4}$. This model structure has been validated 138 in a model selection exercises $[13, 19, 20]$ $[13, 19, 20]$ $[13, 19, 20]$ and is supported anecdotally since working age $_{139}$ males commonly work in the riverine areas, more densely populated by tsetse, and are ¹⁴⁰ more likely to be away from the village working when active screening teams visit $[31]$. $\frac{141}{141}$

Tsetse emerge from a pupal phase P_V as susceptible flies S_V , but upon taking a 142 blood meal on an infected human, they have a higher probability of being exposed E_V 143 and developing infection I_V if it is the first meal of their lifetime, with previously fed, $\frac{144}{144}$ yet uninfected, tsetse G_V having a lower probability of developing infection when taking $_{145}$ an infected blood meal. This phenomenon has been described as the "teneral ¹⁴⁶ effect" [\[32\]](#page-25-9). For a more realistic extrinsic incubation period we sub-divide the exposed $_{147}$ class into three compartments, E_{1V} , E_{2V} , E_{3V} , such that the time a tsetse is exposed is $\frac{148}{148}$ gamma-distributed, rather than exponential. In the present study we assume that blood ¹⁴⁹ meals taken on animals other than humans do not contribute to infections, with animal ¹⁵⁰ infection not explicitly modelled. We note that an "animal transmission" variant of our ¹⁵¹ model exists $[13, 16, 19, 20]$ $[13, 16, 19, 20]$ $[13, 16, 19, 20]$ $[13, 16, 19, 20]$, however there is strong evidence to suggest animals do not $_{152}$ form a maintenance reservoir and, if there is some animal transmission in the DRC, the contribution is relatively small and geographically variable — we would expect it to $_{154}$ slow progress towards, but not prevent EoT. We therefore only analyse the "no animal 155 transmission" variant here. 156

We parameterise the model with both fixed values, predominantly biological 157 constants that will not change in different locations, and fitted values for parameters ¹⁵⁸ that are location dependent (Table [1\)](#page-8-0). The fitted parameters are for the basic ¹⁵⁹ reproduction number (R_0) , the proportion of the human population classed as low-risk $_{160}$

Fig 2. Compartmental gHAT model.

The purple and blue boxes denote the low-risk and high-risk human infection states, respectively. Low-risk people, who randomly participate in active screening are given the subscript H1 and high-risk people, who do no participate, have the subscript H4 (this notation is used to align with previously published versions of this model). Tsetse dynamics are given by red boxes. A proportion $f_A = 1 - f_H$ of tsetse bites will be taken on non-human animals, but this does not contribute to the infection dynamics. This figure is adapted from Crump et al. [\[8\]](#page-23-7) under a CC-BY licence.

> (k_1) , the relative number of bites tsetse take on high-risk people (r) , the diagnostic $\frac{1}{161}$ algorithm specificity in active screening (Spec), the proportion of stage 2 passive cases $_{162}$ reported in 1998 $(u(1998))$, the treatment rate for stage 1 infection from 1998 (η_H^{post}) , 163 the combined treatment rate and disease-induced death rate from stage 2 infection 164 before 1998 (γ_H^{pre}), the combined treatment rate and disease-induced death rate from 165 stage 2 infection from 1998 (γ_H^{post}), the post-1998 midpoint year for passive screening 166 improvement (d_{change}) , the relative improvement in the passive stage 1 detection rate $_{167}$ $(\eta_{H_{\text{amp}}})$, the relative improvement in the passive stage 2 detection rate $(\gamma_{H_{\text{amp}}})$, the 168 speed of improvement in the passive detection rate (d_{steep}) , the overdispersion $_{169}$ parameter for active detection (disp_{act}), and the overdispersion parameter for passive 170 detection (disp_{pass}). All model parameters are given in Table [1.](#page-8-0) 171

> Several of these parameters $(\eta_H^{\text{post}}, \gamma_H^{\text{post}}, \gamma_H^{\text{pre}}, d_{\text{change}}, \eta_{H\text{amp}}, \gamma_{H_{\text{amp}}}, d_{\text{steep}})$ together combine to parameterise the effect of passive screening (where individuals 173 self-present to fixed health facilities for testing). Prior to 1998, there was very limited $_{174}$ testing capacity with diagnostics not commonly available in health facilities [\[41\]](#page-26-0), hence ¹⁷⁵ we assume a lower detection rate for stage 2 infection before this year and no detection 176 in stage 1, where symptoms are less severe and less specific to gHAT. From 1998, the $\frac{177}{177}$ introduction of the card agglutination test for trypanosomes $(CATT)$ enabled an 178 increased chance of detection for both stage 1 and stage 2 infections $[42]$. The continued $_{179}$ improvement in availability of diagnostics, including rapid diagnostic tests $(RDTs)$ in 180 the 2010s [\[43\]](#page-26-2), further improved the passive screening system and therefore the rate of $\frac{181}{181}$ passive detection. Thus, we fully parameterise the rate of leaving stage 1 and stage 2 182 infections in year Y, respectively, as: 183

$$
\eta_H(Y) = \begin{cases} 0, & \text{if } Y < 1998, \\ \eta_H^{\text{post}}\left(1 + \frac{\eta_{H_{\text{amp}}}}{1 + \exp(-d_{\text{steep}}(Y - d_{\text{change}}))}\right), & \text{otherwise.} \end{cases}
$$
(1)

$$
\gamma_H(Y) = \begin{cases} \gamma_H^{\text{pre}}, & \text{if } Y < 1998, \\ \gamma_H^{\text{post}} \left(1 + \frac{\gamma_{H_{\text{amp}}}}{1 + \exp(-d_{\text{steep}}(Y - d_{\text{change}}))} \right), & \text{otherwise.} \end{cases}
$$
(2)

In addition, active screening, where mobile teams visit endemic villages with the aim 185 of screening as many people as possible for infection, is simulated in the model as an ¹⁸⁶ annual event. A random selection of people from the low-risk group N_{H1} , using a 187 hypergeometric probability distribution, are tested for gHAT infected, with diagnostic ¹⁸⁸ sensitivity and specificity then applied based on binomial probabilities. We assume the ¹⁸⁹ diagnostic algorithm have sensitivity (Sens) of 91% and specificity (Spec) fitted to match data in the study area. The true positives detected by the model are then 191 assumed to be treated and so moved to the recovering class R_{H1} , while false negatives 192 remain undetected. In this study, which focuses on the health zone of Mosango, we additionally assume that post-2015, specificity is 100% . This is because video confirmation of the parasites' presence has been used in addition to other diagnostic $_{195}$ tests in this location [\[44\]](#page-26-3). Visualisation of the parasite to confirm a case by more than $_{196}$ one person means there is little chance of false positives being recorded. ¹⁹⁷

Vector control has been carried out in several areas of the DRC and has been seen to 198 have a large impact on the infection dynamics [\[12\]](#page-24-1). Therefore, the model is flexible to 199 include deployment of "tiny targets" used to trap tsetse [\[30\]](#page-25-7). However, for the health ²⁰⁰ zone of Mosango in the data period 2000–2020, there has been no tsetse control and this ₂₀₁ is not included in the model fitting of our simulations.

We could choose to simulate this model structure with at least two distinct methods: $_{203}$ as a deterministic model of ordinary differential equations (ODEs), or as a stochastic ω

184

Notation	Description	Fixed value/Fitted prior*	Source
N_H	Total human population size in 2015^{\dagger}	Fixed for each location	$\overline{33}$
μ_H	Natural human mortality rate	5.4795×10^{-5} days ⁻¹	[34]
B_H	Total human birth rate	$=\mu_H N_H$	
σ_H	Human incubation rate	0.0833 days^{-1}	$[35]$
φ_H	Stage 1 to 2 progression rate	0.0019 days^{-1}	[7, 36]
ω_H	Recovery rate or waning-immunity rate	$0.006 \ \text{days}^{-1}$	[31]
Sens	Active screening diagnostic sensitivity	0.91	$[37]$
B_V	Tsetse birth rate (per capita rate of depositing new pupae) ^{\ddagger}	$0.0505 \ \text{days}^{-1}$	[29]
ξ_V	Rate of pupal development to adult flies	0.037 days $^{-1}$	[29]
K	Pupal carrying capacity [§]	$= 111.09 N_H$	$[29]$
$\mathbb{P}(\text{pupate})$	Probability of a pupa surviving to emerge as an adult fly	0.75	[29]
μ_V	Tsetse mortality rate	0.03 days^{-1}	[35]
σ_V	Tsetse incubation rate	0.034 days^{-1}	[38, 39]
α	Tsetse bite rate	0.333 days^{-1}	$\left[11\right]$
p_V	Probability of tsetse infection per single infective bite	0.065	$[35]$
ε	Reduced susceptibility factor for non-teneral flies	0.05	$[13]$
f_H	Proportion of blood-meals on humans	0.09	[40]
R_0	Basic reproduction number	$1 + \text{Exp}(10)$	
\mathcal{r}	Relative bites taken on high-risk humans	$1 + \Gamma(3.68, 1.09)$	
k_1	Proportion of low-risk people	B(16.97, 3.23)	
	Treatment rate from stage 1, 1998 onwards	$\Gamma(3.54, 5.32 \times 10^{-5})$	
$\eta_H^{\text{post}}\\ \gamma_H^{\text{post}}$	Combined treatment and disease-induced death rate from	$\Gamma(2.45, 0.00192)$	
	stage 2, 1998 onwards		
$b_{\gamma_H^{\rm pre}}$	Relative treatment/death rate from stage 2 factor, pre-1998	B(1, 1)	
Spec	Active screening diagnostic specificity	$0.998 + (1 - 0.998) B(7.23, 2.41)$	
u(1998)	Proportion of stage 2 cases reported from passive screening	B(20, 40)	
	in 1998		
d_{change}	Midpoint year for passive improvement	$2000 + (2017 - 2000) B(5, 6)$	
$\eta_{H_{\rm amp}}$	Relative improvement in passive stage 1 detection rate	$\Gamma(2.013, 1.049)$	
$\gamma_{H_{\rm amp}}$	Relative improvement in passive stage 2 detection rate	$\Gamma(1.001, 5)$	
$d_{\rm steep}$	Speed of improvement in passive screening detection rate	$\Gamma(39.57, 0.0270)$	
$\operatorname{disp}_{\operatorname{act}}$	Overdispersion parameter for active detection	B(1, 2499)	
$\operatorname{disp_{pass}}$	Overdispersion parameter for passive detection	B(1, 35713)	

Table 1. Model parameterisation. Notation, a brief description of the parameter, either the fixed value used or the prior distribution used in fitting, and a source for the fixed parameters.

[∗]Priors given by Exp(.), Γ(.) and B(.) are the exponential, gamma (parameterised with shape and scale) and beta distributions, respectively. †The model is internally scaled such that the population size in all years corresponds to the population in 2015 (outputs are back-transformed to reflect an assumed annual population growth rate of 3% across the DRC).

[‡]The value of B_V was chosen to maintain constant population size in the absence of vector control interventions.

 $§$ The value of K was chosen to reflect the observed bounce back rate.

model using the tau-leaping algorithm. In this study, we focus on the stochastic model $_{205}$ variant (which has previously been used for village-level or health-zone-level ²⁰⁶ simulation $[23, 45]$ $[23, 45]$, also making comparisons back to the previously-studied 207 deterministic version [\[8\]](#page-23-7). ²⁰⁸

The stochastic tau-leaping model is evaluated using a 5-day time step (see [S1 Text\)](#page-22-0) ²⁰⁹ and only considers stochastic events in the human component. The tsetse component is $_{210}$ updated at each time step using a Runge–Kutta method to implement a ODE system. ²¹¹ This choice is due to the difficulty of modelling tsetse explicitly, since the exact number $_{212}$

> of tsetse is unknown in the model; we instead opt to use an effective tsetse density m_{eff} , $_{213}$ which is equal to the product of the vector-to-host ratio and the probability of human $_{214}$ infection per single infective bite. We non-dimensionalise the vector equations by scaling ²¹⁵ by N_H/N_V , the ratio of human and vector population sizes, such that the effective $\qquad 216$ probability of human infection per single infective tsetse bite (m_{eff}) is defined as $_{217}$ $p_H N_V / N_H$, where p_H is the vector-to-human transmission probability. The tsetse ODE 218 simulations will result in a good approximation to a full stochastic simulation, since the ²¹⁹ tsetse dynamics occur on faster timescales to humans and their larger population size 220 mean the stochastic effects will be relatively smaller [\[23\]](#page-25-0).

The full model is described by the events table and ODEs in Table [2.](#page-9-0)

Table 2. Full model equations. Events table for the stochastic tau-leaping model for humans and deterministic ODEs for the tsetse dynamics.

	Event description	Transition		Rate	
Humans	Exposure to infection	$S_{Hi} \rightarrow S_{Hi} - 1,$ $E_{Hi} \rightarrow E_{Hi} + 1$		$\alpha m_{\text{eff}} f_i \frac{S_{Hi}}{N_{Hi}} I_V$	
	Progression to stage 1	$E_{Hi} \rightarrow E_{Hi} - 1$, $I_{1 Hi} \rightarrow I_{1 Hi} + 1$		$\sigma_H E_{Hi}$	
	Progression to stage 2	$I_{1Hi} \rightarrow I_{1Hi} - 1$, $I_{2Hi} \rightarrow I_{2Hi} + 1$		$\varphi_H I_{1Hi}$	
	Treatment from stage 1	$I_{1Hi} \rightarrow I_{1Hi} - 1$, $R_{Hi} \rightarrow R_{Hi} + 1$		$\eta_H(Y)I_{1Hi}$	
	Treatment or death from stage 2	$I_{2Hi} \rightarrow I_{2Hi} - 1$, $R_{Hi} \rightarrow R_{Hi} + 1$		$\gamma_H(Y)I_{2Hi}$	(3)
	Recovery after treatment	$R_{Hi} \rightarrow R_{Hi} - 1$, $S_{Hi} \rightarrow S_{Hi} + 1$		$\omega_H R_{Hi}$	
	Natural birth/death from exposed	$E_{Hi} \rightarrow E_{Hi} - 1$, $S_{Hi} \rightarrow S_{Hi} + 1$		$\mu_H E_{Hi}$	
	Natural birth/death from stage 1	$I_{1Hi} \rightarrow 1_{1Hi} - 1$, $S_{Hi} \rightarrow S_{Hi} + 1$		$\mu_H I_{1Hi}$	
	Natural birth/death from stage $2\,$	$I_{2Hi} \rightarrow I_{2Hi} - 1$, $S_{Hi} \rightarrow S_{Hi} + 1$		$\mu_H I_{2Hi}$	
	Natural birth/death from recovering	$R_{Hi} \rightarrow R_{Hi} - 1, \quad S_{Hi} \rightarrow S_{Hi} + 1$		$\mu_H R_{Hi}$	
T setse	$\begin{array}{lcl} \displaystyle \frac{{\rm d}P_V}{{\rm d}t} & = & B_V N_H - (\xi_V + \frac{P_V}{K}) P_V \\ \displaystyle \frac{{\rm d}S_V}{{\rm d}t} & = & \displaystyle \xi_V \mathbb{P}({\rm pupate}) P_V - \alpha S_V - \mu_V S_V \\ \displaystyle \frac{{\rm d}E_{1V}}{{\rm d}t} & = & \displaystyle \alpha \big(1 - f_T(t)\big) p_V \big(\sum_i f_i \frac{(I_{1Hi} + I_{2Hi})}{N_{Hi}} + f_A \frac{I_A}{N_A} \big) (S_V + \varepsilon G_V) \end{array}$ $-(3\sigma_V + \mu_V + \alpha f_T(t))E_{1V}$ $\frac{\mathrm{d}E_{2V}}{\mathrm{d}t}$ = $3\sigma_V E_{1V} - (3\sigma_V + \mu_V + \alpha f_T(t)) E_{2V}$ $\frac{\mathrm{d}E_{3V}}{\mathrm{d}t} = 3\sigma_V E_{2V} - (3\sigma_V + \mu_V + \alpha f_T(t)) E_{3V}$ $\begin{array}{rcl} \frac{dI_V}{dt}&=&3\sigma_V E_{3V}-(\mu_V+\alpha f_T(t))I_V\\ \frac{dG_V}{dt}&=&\alpha(1-f_T(t))\Big(1-p_V\big(\sum_if_i\frac{(I_{1Hi}+I_{2Hi})}{N_{Hi}}+f_A\frac{I_A}{N_A}\big)\Big)S_V \end{array}$ $-\alpha\Big(f_T(t)+\big(1-f_T(t)\big)p_V\varepsilon\big(\sum_if_i\frac{(I_{1Hi}+I_{2Hi})}{N_{rr}}+f_A\frac{I_A}{N_{\star}}\big)\Big)G_V$ $-\mu_V G_V$				

 222

Model fitting 223

The posteriors of our 14 fitted parameters (see Table [1\)](#page-8-0) are obtained for each location $_{224}$ using particle Markov chain Monte Carlo (pMCMC) with the stochastic model 225 described in Table [2.](#page-9-0) We use the adaptive Metropolis–Hastings random walk algorithm ²²⁶ described in Crump et al. $[8]$, but rather than direct computation of the likelihood, we $\frac{227}{20}$ obtain an estimate using a particle filter (otherwise known as sequential Monte Carlo). ²²⁸ We cannot directly compute the likelihood of our stochastic model since we cannot 229 consider the infinite number of possible trajectories the model could take due to the ²³⁰ random nature of the model $[46]$.

Particle MCMC is widely used for stochastic model fitting and seeing an increasing 232 use in mathematical epidemiology $[47, 48]$ $[47, 48]$. Our pMCMC algorithm is the integration of $\frac{233}{2}$ a particle filter to calculate the marginal likelihood into an adaptive ²³⁴ Metropolis–Hastings algorithm. Since we cannot consider all stochastic trajectories, we ²³⁵ construct an estimate using a set of samples (or "particles"). Using the current ²³⁶ parameter set in the MCMC, we simulate the model from the initial state to a data 237 point. At each data point, the particles are assigned weights proportional to the 238 likelihood of the data point. Zero weight particles are removed and re-distributed ²³⁹ according to combine-split resampling [\[49\]](#page-26-10). This process prevents particles with no ²⁴⁰ likelihood propagating forward with no increase in the variance of the marginal ²⁴¹ likelihood. In addition, if the effective sample size (ESS) of the particle filter falls below $_{242}$ the value of half the number of particles, we re-sample the particles according to 243 systematic re-sampling to ensure a high ESS [\[50\]](#page-26-11). After the re-sampling, if it occurs, the $_{244}$ new set of particles is simulated forward to the next data point and the process is ²⁴⁵ repeated sequentially until the end of the data. ²⁴⁶

For each particle trajectory (2000–2020), the value of the likelihood calculation is given by:

$$
LL(\theta|x) = \log(P(x|\theta))
$$

\n
$$
\propto \sum_{i=2000}^{2020} \left(\log \left[\text{BetaBin}\left(A_{D1}(i) + A_{D2}(i) + A_{DU}(i); z(i), \frac{A_{M1}(i) + A_{M2}(i)}{z(i)}, \text{disp}_{\text{act}} \right) \right] + \log \left[\text{Bin}\left(A_{D1}(i); A_{D1}(i) + A_{D2}(i), \frac{A_{M1}(i)}{A_{M1}(i) + A_{M2}(i)} \right) \right] + \log \left[\text{BetaBin}\left(P_{D1}(i) + P_{D2}(i) + P_{DU}(i); N_H, \frac{P_{M1}(i) + P_{M2}(i)}{N_H}, \text{disp}_{\text{pass}} \right) \right] + \log \left[\text{Bin}\left(P_{D1}(i); P_{D1}(i) + P_{D2}(i), \frac{P_{M1}(i)}{P_{M1}(i) + P_{M2}(i)} \right) \right],
$$

for model parameterisation θ , and data point x. The number of cases detected by passive or active screening in year i are given by $P_{D_i}(i)$ and $A_{D_i}(i)$, where the stage is 248 $j = 1, 2$, or unknown, U. Equivalently, $P_{Mj}(i)$ and $A_{Mj}(i)$ are the number of cases 249 detected by passive or active screening in the model. $z(i)$ is the number of people z_{50} actively screened in year i. BetaBin $(m; n, p, \rho)$ gives the probability of obtaining m 251 successes out of n trials with probability p and overdispersion parameter ρ .

We calibrate the number of particles used in the particle filter by comparing the 253 output likelihood for a range of options. We ran 10,000 parameter samples from a ²⁵⁴ previously obtained joint posterior distribution in the particle filter with between 5 and ²⁵⁵ 500 particles (Fig [3\)](#page-12-0). We thus choose to use 50 particles for our model fitting, since this ²⁵⁶ number is low and so would limit computation time, but it is also high enough to 257

> provide stability in the log likelihood estimation; additional particles showed little ²⁵⁸ change in median value or variance.

> As in Crump et al. [\[8\]](#page-23-7), the MCMC process is fully-automated in outputting $_{260}$ posteriors and includes three phases run across two independent chains. Firstly, a ²⁶¹ transient phase with single-site updates only to determine where in parameter space $_{262}$ sampling should begin. Secondly, an adaptive phase to start to learn the covariance 263 matrix of the posterior, such that an efficient proposal can be obtained. And thirdly, ²⁶⁴ the sampling phase to obtain the posteriors. The transient phase lasts for 1,000 265 iterations, the adaptive phase is continued until using the Gelman-Rubin statistic [\[51\]](#page-26-12), ²⁶⁶ we have $R_{\text{within}}^{(i,j)} \leq 1.1$ and $R_{\text{between}}^{(i)} \leq 1.5$ for parameter i and chain j, for a maximum 267 of 100,000 iterations, and the sampling phase ends when $R_{\text{between}}^{(i)} \leq 1.2$ and the ESS of 268 the pMCMC chain is at least 1,000. The ESS is here defined as the minimum value of $_{266}$ all the fitted parameters, where it is calculated using the autocorrelation of the thinned $_{270}$ sample, such that there are $1,000$ values for each chain [\[52\]](#page-26-13).

> These phases are shown in an example chain for fitting the health zone of Mosango 272 in Fig [3.](#page-12-0) We see that well mixed chains after the burn in, throughout the sampling $_{273}$ phase, (shown by the green background) result in good convergence below the threshold. ²⁷⁴ The chains terminate when the ESS threshold is reached in reasonable time.

Future projections and estimating EoT 276

We simulate future projections beyond the end of our data set to 2050, using parameters $\frac{277}{277}$ the parameters obtained in model fitting. We adopt a "continuation" strategy, whereby ²⁷⁸ we maintain the same interventions in the future as the present ones. Annual active $\frac{279}{279}$ screening continues at a coverage equal to the mean annual coverage of the last five years of data and the rate of detection in passive screening remains unchanged.

Model outputs include the annual number of active cases given the number of people $_{282}$ screened, the number of passive cases detected and the number of new infections. While 283 the actual number of new infections is unknowable (as the timescale from infection to ²⁸⁴ detection can be long and furthermore many people are missed in screening), we infer $\frac{285}{2}$ the number of new infections each year both historically and beyond 2020 assuming 286 interventions continue at the same level.

From these simulations, we calculate the probability of EoT (PEoT) as the 288 proportion of model realisations that reach the target of EoT. For calculating PEoT for ²⁸⁹ all the independent health areas of a health zone, we take the product of all health area ²⁹⁰ PEOT values. Hence, we are also able to predict the expected year of EoT, in both 291 health areas and health zones, as the median year EoT is reached in simulations.

$\textbf{Results}$ 293

Fitting to health areas $\frac{294}{2}$

On performing the fitting process on data for each of the 16 health areas independently, ²⁹⁵ the fitting ended successfully in each case, with an ESS of at least 1,000 and good $_{296}$ convergence that satisfied our threshold, such that for all our health area fits, we had $_{297}$ $R_{\text{between}}^{(i)} \leq 1.00867.$

Comparing the relevant model outputs back to the data, we have a good correspondence for all health areas. We show example outputs for two of the sixteen $\frac{300}{200}$ health areas of Mosango (Fig [4\)](#page-14-0), chosen as a low burden health area (Kinzamba I, 15 $\frac{301}{200}$

Fig 3. pMCMC fitting outputs.

(Left) Estimates of the negative log posterior probability (NLPP) given by different numbers of particles used by our particle filter. Each box plot consists of 10,000 values consisting of five stochastic realisations from a posterior of 2,000 values. (Right) Iterations of example pMCMC chains. The top plot shows the two independent chains and values for the NLPP for 50 particles. The middle plot shows the between chain convergence diagnostic as the number of iterations increases after the burn in. The bottom plot shows the effective sample size (ESS) after the burn in, which is taken to be the minimum value of the autocorrelation of the thinned sample for all the fitted parameters. Dashed lines show where thresholds for completion lie. Background colours indicate phase of the pMCMC: red for the (relatively short) transient phase, blue for the adaptive phase, and green for the sampling phase.

> cases reported in 2000–2020) and the highest burden health area (Kinzamba II, 428 $_{302}$ [c](#page-22-1)ases reported in 2000–2020). Outputs for all additional health areas are shown in $S2$ 303 $Text.$ 304

> Fitting the stochastic model took three to ten times times as long to meet our fitting 305 cessation criteria compared to fitting the deterministic model to the same data, with ³⁰⁶ both computations performed on the same cluster with the deterministic code ³⁰⁷ parallelised over two cores and the stochastic code over ten cores. The longest 308 computation times occurred when substantially more MCMC iterations were required to ³⁰⁹ meet the ESS threshold, and the shorter times were when no additional sampling was $\frac{310}{2}$ required beyond the number needed for deterministic fitting (typically $\langle 200, 000 \rangle$ 311 iterations). 312

> For both example health areas, the expected trend in reported cases is well captured $\frac{313}{2}$ with almost all data points falling within the displayed 95% credible intervals. Generally, higher historical screening coverage resulted in higher active case reporting, $\frac{315}{2}$ while passive case numbers are more stable, but with a decline throughout the study $\frac{316}{2}$ period, as the underlying expected number of new infections declines. The expected ³¹⁷ number of new infections in the model also decreases with these trends. $\frac{318}{2}$

> The basic reproduction number R_0 is a fitted parameter of the model, which defines $\frac{319}{2}$ the expected number of new infections generated from a single infected in a susceptible $\frac{320}{20}$ population. For gHAT, this number is very close to, but greater than one $[8, 13, 53]$ $[8, 13, 53]$ $[8, 13, 53]$. $\qquad \qquad \text{and}$ This can be explained by the fact that gHAT is a slow-moving endemic disease and so $\frac{322}{2}$ infection only needs to cause one more (over several years) in order to maintain endemic ₃₂₃ levels of transmission. Several factors will affect the local basic reproduction number for ³²⁴ each health area, such as the number of tsetse in the location or the geography of the 325 region defining the contact patterns and hence transmission rate of infection $[3]$.

> The geographical distribution of R_0 in Mosango health zone shows there is $\frac{327}{2}$ substantial variation between health areas (Fig [5\)](#page-15-0), hence justifying the use of a $\frac{328}{26}$ finer-scale model. Kinzamba II health area $(A3)$ has the largest median value with 329 $R_0 = 1.04$ and the R_0 posterior distribution is shifted to be be larger than most other $\frac{330}{20}$ health areas. This corresponds with the largest number of cases being detected in this $\frac{331}{331}$ health area. Health areas with the fewest cases, such as Kasay $(A1)$, have the lowest R_0 332 values. However, the median R_0 values from the fitting show all health areas have $\frac{333}{2}$ $1 \leq R_0 \leq 1.04$. In all cases the posterior has greatly deviated from the exponential (but $\frac{334}{100}$ relatively flat) prior distribution. $\frac{335}{2}$

> Values for the parameter $u(1998)$, which is the proportion of stage 2 cases reported 336 from passive screening in 1998, are much more similar across the health zone. The 337 median values are in the range $0.29 \le u(1998) \le 0.37$ and the posterior distributions all $\frac{338}{2}$ substantially overlap. This parameter determines the level of under-reporting of $\frac{339}{2}$ infection, since it defines the the proportion of late-stage cases detected in passive ³⁴⁰ screening, of those that are not detected by active screening. Due to similar access to $_{341}$ fixed health facilities across the health zone, it is logical that there would not be major ³⁴² variation in this parameter across the health zone. For most health areas there is not ³⁴³ significant deviation from our informed prior distributions, indicating there may be insufficient data to show difference from these distributions. However, there are examples where model fitting highlights spatial differences. The reduced value of the ³⁴⁶ median of the posterior distribution in health area A9 (Kumbi Mbwana) indicates $_{347}$ passive screening is detecting fewer than expected cases here, given the relatively large ³⁴⁸ R_0 value, whereas the larger posterior values in A10 (Mangungu) indicate passive $\frac{349}{2}$ screening is performing well. These results contrast with the health area with most data, $\frac{350}{200}$ A3 (Kinzamba II), where the median estimated value of $u(1998)$ is only slightly higher $\frac{351}{20}$

Fig 4. Model fitting outputs in example health areas.

Data for the number of people actively screened and the active and passive cases reported are displayed as solid black lines for two health areas: Kinzamba I and Kinzamba II (labelled as A2 and A3 respectively in this analysis). This is compared with modelling outputs for active and passive cases and the number of new infections in each year given as coloured box plots. The median value of the box plots is shown as a white line, with outer boxes and whiskers representing 50% and 95% credible intervals respectively. No data line is shown for new infections, since this cannot be directly observed. Maps of the health area locations with the Mosango health zone are shown in the top right of each column.

Fig 5. Geographical distribution of model parameters in Mosango health zone.

The geographical distribution of the median values for the basic reproduction number R_0 and the proportion of stage 2 cases reported from passive screening $u(1998)$ is shown in maps of the health zone. Each health area is labelled A1–A16, with the full posterior distribution given in histograms on the right. The median value is shown by a horizontal coloured line, aligned with the color scale of the map. The prior distribution is shown on the histograms as a solid black line, although with a relatively low probability density in the displayed region for the R_0 histograms, and is the same for each health area. The names of health areas A1–A16 are given in [S1 Text.](#page-22-0) Shape files used to produce this map were provided by Nicole Hoff and Cyrus Sinai under a CC-BY licence (current versions can be found at <https://data.humdata.org/dataset/drc-health-data>).

 $\frac{1}{352}$ than the prior. $\frac{352}{252}$

$\mathbf{Comparison of fitting approaches}$ $\mathbf{3}$

In addition to fitting the stochastic model to the health area data, we performed that $\frac{354}{4}$ same fitting methodology with data from the full health zone, and also fit the $\frac{355}{2}$ deterministic model variant to the health zone data using the original methodology of $\frac{356}{2}$ Crump et al. $[8]$. In order to compare between the three approaches, we aggregated $\frac{357}{257}$ together the health area data by taking the sum of the output model realisations for $\frac{358}{2}$ each health area, to create health zone distributions. $\frac{359}{259}$

All three fitting approaches provide very similar outputs that capture the dynamics $\frac{360}{200}$ seen in the data, providing confidence that all of these methods are appropriate for $\frac{361}{200}$ model fitting (Fig [6\)](#page-17-0). In particular, the health zone fitting shows there is very little $\frac{362}{100}$ difference in median between outputs of the deterministic and stochastic model variants, ₃₆₃ shown as blue and red boxes respectively in Fig [6.](#page-17-0) The stochastic model variant does $_{364}$ indicate more uncertainty in the number of new infections since the random nature of the model demonstrates a wider range of outcomes can still match the data. There is $\frac{366}{900}$ also more uncertainty in the stochastic model in later years where gHAT is closer to $\frac{367}{267}$ elimination, shown by the longer time span in the probability of EoT increasing from ³⁶⁸ zero to one. Hence, this provides evidence that using the stochastic model is more appropriate for low infection numbers, as the uncertainty is representative. This is $\frac{370}{20}$ particularly true when considering the smaller population sizes of single health areas $\frac{371}{20}$ (Fig [7\)](#page-18-0). The larger uncertainty in the versions that use stochastic projections is ³⁷² important for projecting cases in future years, where we would expect a further decline, ³⁷³ given current intervention strategies, and more realistically captures the uncertainty in ³⁷⁴ when EoT could occur. We also note that using the posterior of the deterministic fitting $\frac{375}{2}$ in the stochastic model projections provides outputs more similar to the full stochastic $\frac{376}{2}$ output, rather than the deterministic one (Fig [7,](#page-18-0) see [S2 Text](#page-22-1) for aggregated health area $\frac{377}{2}$ results). This indicates that there are greater fundamental differences between the $\frac{378}{276}$ deterministic and stochastic model variants than can be accounted for in model fitting. ³⁷⁹

For modelling at different spatial scales, while the outputs are very similar for the $\frac{380}{200}$ health zone and aggregated health areas, it is clear that there is additional benefit of $\frac{381}{381}$ using a more fine-scaled approach (Fig 6). The aggregation of health area models $\frac{382}{2}$ provides the best fit to the health zone data (green boxes in Fig 6). Some information is $\frac{383}{100}$ lost on the location of active screenings and cases when the data is combined for the $\frac{384}{384}$ purpose of model fitting to health zones, and so the more nuanced health area fitting $\frac{385}{100}$ process is more likely to recover the infection dynamics.

Future projections and estimating EoT 387

We also compare differences in health area and health zone fitting, by considering $\frac{388}{100}$ projections for future infections and specifically the probability of EoT. For each health ³⁸⁹ area, we calculate the annual probability of EoT (PEoT) as the proportion of samples $\frac{390}{2}$ where EoT has been achieved, assuming continued interventions in future years. Since, $\frac{391}{200}$ EoT is defined as when there are no future transmission events, this requires simulating $\frac{392}{2}$ the model beyond just the first year there are no new infections to ensure people ³⁹³ infected for long periods do not cause onward transmission much later.

We see that in each of the health areas of Mosango there is a very high PEoT by $\frac{395}{2}$ 2030 (Fig [8\)](#page-20-0). Each health area in isolation has a PEoT by 2030 greater than 0.94, with ³⁹⁶ the lowest in Kinzamba II (health area A3). However, the probability of achieving EoT $_{397}$ in all the health areas, and thus the entire health zone, will be substantially lower as it

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.08.17.23294225;](https://doi.org/10.1101/2023.08.17.23294225) this version posted August 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted

Data for the number of people actively screened and the active and passive cases reported is displayed as solid black lines. The coloured box plots show annual model outputs for different fitting approaches, where blue boxes show the deterministic health zone model, red shows the stochastic health zone model, and green shows the aggregated stochastic health area models. The median value of the box plots is shown as a white line, with box plot whiskers representing 95% credible intervals. The bottom panel shows the probability of EoT from 2000–2050 assuming a continuation of interventions.

It is made available under a CC-BY 4.0 International license. **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. medRxiv preprint doi: [https://doi.org/10.1101/2023.08.17.23294225;](https://doi.org/10.1101/2023.08.17.23294225) this version posted August 20, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted

Data for the number of people actively screened and the active and passive cases reported is shown by solid black lines. Coloured box plots show annual model outputs for different methods for both model fitting and model projections. The light blue boxes show the deterministic model fitting with deterministic projections, the light purple shows the deterministic model fitting with stochastic projections, and light red shows the stochastic model fitting with stochastic projections. The median value of the box plots is shown as a white line, with box plot whiskers representing 95% credible intervals. The bottom panel shows the probability of EoT from 2000–2050 assuming a continuation of interventions.

is equal to the product of the PEoTs. Indeed the PEoT in all health areas by 2030 is ³⁹⁹ 0.82 (solid black line in Fig [8\)](#page-20-0), which is comparable to the same calculation used, but $\frac{400}{400}$ with the health zone model that gives a probability of 0.86 (dotted grey line in Fig [8\)](#page-20-0). $_{401}$

We also display the expected year of EoT, calculated as the median year from all $\frac{402}{402}$ model realisations (Figure [8\)](#page-20-0). For each health area, the expected year of EoT are all in $\frac{403}{403}$ the past. This is consistent with the fact that when considering a smaller area there is a $_{404}$ higher chance of elimination in that area only. Furthermore, while EoT may have occurred in health areas (i.e. the last transmission events may have already occurred), ⁴⁰⁶ there could still be undetected infections, that are yet to be reported as cases due to the $_{407}$ long infection time scales of gHAT [\[4\]](#page-23-3). And indeed, while local EoT may have already $\frac{408}{408}$ occurred in selected health areas, we still predict a later median year of 2024 for EoT ⁴⁰⁹ for all health areas of Mosango, which aligns with the results for modelling at the health $\frac{410}{410}$ zone level. We also re-iterate that this is to have a 50% probability of EoT, and to have 411 higher confidence that EoT has truly occurred, it would be recommended for vertical $_{412}$ interventions to remain in place for several more years, as would also be recommended $\frac{413}{413}$ based on current WHO guidelines for active screening. ⁴¹⁴

Discussion $\frac{1}{415}$

By implementing a pMCMC fitting algorithm, we have been able to fit a stochastic $\frac{416}{416}$ infection model to historical gHAT screening and case data. This process is more 417 complex and computationally intensive than fitting a deterministic model with a more $\frac{418}{418}$ traditional MCMC approach. With the particle filter we are able to account for $\frac{419}{419}$ stochastic variations in the infection dynamics with improved realism. Moreover, $\frac{420}{420}$ pMCMC allows us to fit the multiple parameters of our stochastic model in a reasonable ⁴²¹ time frame, rather than relying on the deterministic analogue.

Previous modelling work has used the parameters determined from fitting a $_{423}$ deterministic model to make projections of future infection dynamics in a stochastic ⁴²⁴ model variant [\[4,](#page-23-3) [15,](#page-24-11) [45\]](#page-26-6). We have shown here that this gives a good approximation to $\frac{425}{425}$ using using the parameters obtained from stochastic fitting. In particular, we show that $_{426}$ in fitting different models to health zone data for Mosango, both deterministic and 427 stochastic models produce very similar results (Fig 6). Although we note that results 428 can diverge more in the future projections in the approach to elimination (see [S2 Text\)](#page-22-1). $_{429}$

In fitting stochastic models suited to where there are low number of infections, we have also expanded the range of previously modelled locations, to include the small $\frac{431}{431}$ scale approach of health area modelling. This new modelling at a health area spatial $\frac{432}{4}$ scale provides highly specific results that captures the full heterogeneity and focal 433 nature of gHAT infections. We show that by using information in the data on the 434 health area location for screening activities and cases, we can obtain a better fit to the data (Fig [6\)](#page-17-0), since screening activities are directly mapped to the specific health areas $\frac{436}{4}$ they occurred in. $\frac{437}{437}$

The main benefit of health area modelling, however, will be in future projections. A $_{438}$ more fine-scaled approach will bring added realism into modelling by more accurately $\frac{439}{4}$ reflecting proposed scenarios and providing more flexibility in the scenarios that can be ⁴⁴⁰ modelled. For example, increasing active screening coverage in specific region of a $_{441}$ health zone, or only implementing vector control in the relevant high-tsetse density $\frac{442}{420}$ areas can now be modelled, as opposed to blanket changes across the whole health zone ⁴⁴³ $(\sec S2 \text{ Text})$.

We choose to model all health areas independently since we know that gHAT $_{445}$

Fig 8. Elimination of transmission (EoT) in Mosango.

Probabilities of EoT for health area by a given year is shown by coloured lines in the top panel, with aggregated health area results shown as a black line and separate health zone model results shown by a dotted grey line. The below panel shows maps of Mosango with median expected years of EoT given by colour. The three maps show three approaches for displaying EoT: for each individual health area, for the health zone using the health area models, and for the health zone using the health zone model. Shape files used to produce this map were provided by Nicole Hoff and Cyrus Sinai under a CC-BY licence (current versions can be found at <https://data.humdata.org/dataset/drc-health-data>).

> transmission is very localised and in many instances there will only be very limited ⁴⁴⁶ movement of both people and tsetse between neighbouring health areas [\[5\]](#page-23-4). However, $\frac{447}{400}$ this is not uniformly the case, and there could be importations of infection between ⁴⁴⁸ neighbouring health areas, which are not considered. Future work would consider ⁴⁴⁹ correlations between infections in health areas that share a border along a river, a typical habitat for tsetse $[6]$, since here the same tsetse population would be infecting $\frac{451}{451}$ humans from both health areas. 452

> In developing our model, we also choose not to consider the presence of possible $\frac{453}{453}$ animal reservoirs or transmission from asymptomatic humans. While $T.b.$ gambiense 454 can be found in animals $[54]$, evidence is inconclusive to this contribution to the 455 transmission cycle with humans [\[55\]](#page-27-2). Previous modelling has been shown that there is ⁴⁵⁶ some evidence that animals may contribute to transmission in some areas, however it is $_{457}$ extremely unlikely that animals could sustain transmission without humans $[16, 20]$ $[16, 20]$. \qquad Modelling has not yet been able to evaluate the evidence for self-curing asymptomatic $\frac{459}{459}$ human infections on transmission and elimination through matching to data, however an asymptomatic model sensitivity analysis has been performed $[56]$. The modelling and $_{461}$ fitting methods presented here could be modified readily to include the animal ⁴⁶² transmission or asymptomatic model variations, however this would further increase $\frac{463}{463}$ time to run the simulation as an additional two or five model parameters would need to $\frac{464}{464}$ be estimated through the pMCMC for the two models respectively.

> Future work should use the principles demonstrated here and expand to provide 466 fitted models for all health areas in the DRC that have sufficient data to be confident in $_{467}$ the results. One drawback of this approach will be the lack of data across all endemic $\frac{468}{468}$ regions, particularly as we approach elimination. In Mosango the minimum number of $\frac{469}{469}$ data points we have was 7 (in health area A1, Kasay), however it is highly likely that 470 some health areas may have fewer data points than this and could render fitting $\frac{471}{471}$ unreliable in those locations. In this instance, options could overcome this issue include 472 amalgamation of neighbouring health areas of similar (believed) prevalence to create $\frac{473}{473}$ sub-health-zone but larger-than-health-area sized regions for an analysis $-$ this 474 approach is demonstrated for the two health areas with fewest data points in Mosango ⁴⁷⁵ in [S1 Text.](#page-22-0) For some locations it may not be recommendable to attempt 476 sub-health-zone level fitting due to data limitations.

> Our model uses data points on active and passive cases and the infection state of ⁴⁷⁸ those cases detected (stage 1 or stage 2), where available, to determine the likelihood $_{479}$ and thus inform the model parameters. Since 2020 , the DRC have expanded first-line $_{480}$ treatments for gHAT patients to include fexinidazole $[10, 57]$ $[10, 57]$, it is no longer necessary to $\frac{481}{100}$ determine infection stage, since the treatment is suitable for both stages and the process $\frac{482}{482}$ of determining infection stage, visualising parasites in cerebrospinal fluid, requires a ⁴⁸³ lumbar puncture and is unpleasant for the patients. While this is a great benefit for $\frac{484}{90}$ patients, and results in a reduced incentive to avoid treatment, there is a loss of information in people's infection status. For the purpose of model fitting, more 486 information is always beneficial to better match reality $[17]$ and may lead to deterioration in our ability to fit models unless additional information is recorded such ⁴⁸⁸ as infection symptoms, as to give a proxy for this lost stage information. ⁴⁸⁹

> Additionally, we note that fitting models for all health areas is more computationally $\frac{490}{4}$ intensive than fitting to health zones. This is in part due to the fact that there are $\frac{491}{491}$ many more health areas of the DRC and so there are simply more locations; approximately 1200 analysable health areas based on the 2000–2020 HAT Atlas data, ⁴⁹³ assuming a minimum of 10 data points required for fitting, currently available shape ⁴⁹⁴ files to define health area boundaries, and good estimates of health area population $\frac{495}{4}$

> sizes. Also, the stochastic fitting methodology is more intensive than deterministic $\frac{496}{4}$ fitting if we choose to fit with this methodology. In the pMCMC, we have to simulate $_{497}$ multiple trajectories to be able to evaluate the likelihood of a parameter set rather than ⁴⁹⁸ the single deterministic trajectory. The model fitting procedure presented here is fully automated, and parallelised to optimise performance on a computer cluster, so while $\frac{500}{500}$ compute times may be longer (three to ten times as long, using five times the number of $\frac{501}{101}$ cores), there is little additional work for the user. However, we have demonstrated in $_{502}$ this manuscript that, for gHAT, fitting using the deterministic model variant provides a $_{503}$ close approximation (Fig [7\)](#page-18-0), which would negate the necessity for this additional $_{504}$ computation time. We note that this will no be true for disease modelling generally; the $_{505}$ long time scales of gHAT infection, slow disease progression and small critical $_{506}$ community size are likely to make this approximation valid $[23]$.

> This study has focused on the computational methodology to allow gHAT $_{508}$ transmission model fitting to health area data in the DRC and does not seek here to $\frac{509}{200}$ make any specific policy recommendations. Our projections simulated from 2020 $\frac{510}{20}$ onwards assume a status quo for interventions and we do not seek to assess the possible ⁵¹¹ impact on changes to interventions. Our study does lay out a appropriate framework ⁵¹² with which to evaluate future health-area-level strategy in further analyses, ensuring $\frac{513}{2}$ models are suitably calibrated to local data and that they can provide very granular $\frac{514}{514}$ recommendations, extending the health zone projection and health economic evaluations $\frac{515}{2}$ $\text{produced previously } [30, 58].$ $\text{produced previously } [30, 58].$ $\text{produced previously } [30, 58].$ $\text{produced previously } [30, 58].$

$\mathbf{Conclusion}$ \blacksquare

In demonstrating that a mechanistic, stochastic infection model can be fitted to $\frac{518}{216}$ different health area data in the DRC, we have added a new framework that can $\frac{519}{2}$ provide highly detailed calibration and projections of future gHAT infections for a range $\frac{520}{20}$ of intervention scenarios. The similarity in fitting stochastic models to data and $\frac{521}{221}$ simulating stochastic models, but using deterministic variants for fitting, validates the $\frac{522}{20}$ approach of previous studies and indicates that stochastic fitting may not always be $\frac{523}{20}$ necessary. The importance of stochastic models however remains clear, in determining 524 time to elimination of transmission and our uncertainty in this.

The greater nuance afforded by smaller-scale health area modelling will further refine $\frac{526}{2}$ the ability to accurately forecast future infections for intervention scenarios, allowing $\frac{527}{20}$ policy makers to better understand the cost and impact of proposed interventions. ⁵²⁸

$\textbf{Supplementary information} \quad \text{13.529}$

S1 Text. Additional methods. An expansion of the mathematical modelling 530 methodology. 531

S2 Text. Additional model outputs. Further comparisons of modelling $\frac{532}{532}$ approaches and full posteriors for health area fitting. 533

$\rm Acknowledgments$

The authors thank PNLTHA-DRC for original data collection and WHO for data access $\frac{535}{2}$ (in the framework of the WHO HAT Atlas [\[3\]](#page-23-2)). We thank Cyrus Sinai and Nicole Hoff ⁵³⁶ from UCLA Fielding School of Public Health for providing health zone-level shape files 537 for the DRC and health area-level for former Bandundu province (current versions can ⁵³⁸

> be found at <https://data.humdata.org/dataset/drc-health-data>). We also thank $\frac{539}{2}$ the HAT MEPP scientific project manager Emily Crowley for her support in project ⁵⁴⁰ organisation and proof-reading this manuscript. ⁵⁴¹

> \mathbf{Right} s retention statement $\begin{bmatrix} 542 \end{bmatrix}$

For the purpose of open access, the author has applied a Creative Commons Attribution $\frac{543}{2}$ (CC-BY) licence to any Author Accepted Manuscript version arising from this ⁵⁴⁴ submission. 545

References

- 1. NTD Modelling Consortium Discussion Group on Gambiense Human African Trypanosomiasis . Insights from quantitative and mathematical modelling on the proposed 2030 goal for gambiense human African trypanosomiasis (gHAT) [version 2; peer review: 2 approved]. Gates Open Research. 2020;3(1553).
- 2. World Health Organization. Global Health Observatory Data Repository; 2023. Available from: [https://www.who.int/data/gho/data/indicators/](https://www.who.int/data/gho/data/indicators/indicator-details/GHO/hat-tb-gambiense/) [indicator-details/GHO/hat-tb-gambiense/](https://www.who.int/data/gho/data/indicators/indicator-details/GHO/hat-tb-gambiense/).
- 3. Franco JR, Cecchi G, Paone M, Diarra A, Grout L, Kadima Ebeja A, et al. The elimination of human African trypanosomiasis: Achievements in relation to WHO road map targets for 2020. PLoS neglected tropical diseases. $2022;16(1):e0010047$.
- 4. Davis CN, Casta˜no MS, Aliee M, Patel S, Miaka EM, Keeling MJ, et al. Modelling to quantify the likelihood that local elimination of transmission has occurred using routine gambiense human African trypanosomiasis surveillance data. Clinical infectious diseases. 2021;72(Supplement 3):S146–S151.
- 5. Franco JR, Simarro PP, Diarra A, Jannin JG. Epidemiology of human African trypanosomiasis. Clinical epidemiology. 2014;6:257.
- 6. Bessell PR, Esterhuizen J, Lehane MJ, Longbottom J, Mugenyi A, Selby R, et al. Estimating the impact of Tiny Targets in reducing the incidence of Gambian sleeping sickness in the North-west Uganda focus. Parasites & Vectors. 2021;14:1–13.
- 7. Checchi F, Funk S, Chandramohan D, Haydon DT, Chappuis F. Updated estimate of the duration of the meningo-encephalitic stage in gambiense human African trypanosomiasis. BMC Research Notes. 2015;8(1):292. doi:10.1186/s13104-015-1244-3.
- 8. Crump RE, Huang CI, Knock ES, Spencer SEF, Brown PE, Mwamba Miaka E, et al. Quantifying epidemiological drivers of gambiense human African Trypanosomiasis across the Democratic Republic of Congo. PLOS Computational Biology. 2021;17(1):1–23. doi:10.1371/journal.pcbi.1008532.
- 9. Büscher P, Cecchi G, Jamonneau V, Priotto G. Human African trypanosomiasis. The Lancet. 2017;390(10110):2397–2409.
- 10. World Health Organization. WHO interim guidelines for the treatment of gambiense human African trypanosomiasis; 2019.

- 11. World Health Organization. Control and surveillance of human African trypanosomiasis: report of a WHO expert committee. World Health Organization; 2013. 984.
- 12. Tirados I, Hope A, Selby R, Mpembele F, Miaka EM, Boelaert M, et al. Impact of tiny targets on Glossina fuscipes quanzensis, the primary vector of human African trypanosomiasis in the Democratic Republic of the Congo. PLoS neglected tropical diseases. 2020;14(10):e0008270.
- 13. Rock KS, Torr SJ, Lumbala C, Keeling MJ. Quantitative evaluation of the strategy to eliminate human African trypanosomiasis in the DRC. Parasites & Vectors. 2015;8(1):532.
- 14. Rock KS, Pandey A, Ndeffo-Mbah ML, Atkins KE, Lumbala C, Galvani A, et al. Data-driven models to predict the elimination of sleeping sickness in former Equateur province of DRC. Epidemics. 2017;18:101–112.
- 15. Aliee M, Casta˜no S, Davis CN, Patel S, Miaka EM, Spencer SE, et al. Predicting the impact of COVID-19 interruptions on transmission of gambiense human African trypanosomiasis in two health zones of the Democratic Republic of Congo. Transactions of The Royal Society of Tropical Medicine and Hygiene. 2021;115(3):245–252.
- 16. Crump RE, Huang CI, Spencer SE, Brown PE, Shampa C, Mwamba Miaka E, et al. Modelling to infer the role of animals in gambiense human African trypanosomiasis transmission and elimination in the DRC. PLOS Neglected Tropical Diseases. 2022;16(7):e0010599.
- 17. Casta˜no MS, Ndeffo-Mbah ML, Rock KS, Palmer C, Knock E, Miaka EM, et al. Assessing the impact of aggregating disease stage data in model predictions of human African trypanosomiasis transmission and control activities in Bandundu province (DRC). PLoS Neglected Tropical Diseases. 2020;14(1):e0007976.
- 18. Pandey A, Atkins KE, Bucheton B, Camara M, Aksoy S, Galvani AP, et al. Evaluating long-term effectiveness of sleeping sickness control measures in Guinea. Parasites & Vectors. 2015;8(1):550.
- 19. Mahamat MH, Peka M, Rayaisse JB, Rock KS, Toko MA, Darnas J, et al. Adding tsetse control to medical activities contributes to decreasing transmission of sleeping sickness in the Mandoul focus (Chad). PLoS Neglected Tropical Diseases. 2017;11(7):e0005792.
- 20. Rock KS, Huang CI, Crump RE, Bessell PR, Brown PE, Tirados I, et al. Update of transmission modelling and projections of gambiense human African trypanosomiasis in the Mandoul focus, Chad. Infectious Diseases of Poverty. 2022;11(1):11. doi:10.1186/s40249-022-00934-8.
- 21. Kaba D, Koffi M, Kouakou L, N'Gouan EK, Djohan V, Courtin F, et al. Towards the sustainable elimination of human African trypanosomiasis in Côte d'Ivoire using an integrated approach. medRxiv. 2023; p. 2023–02.
- 22. de Vries H, Wagelmans APM, Hasker E, Lumbala C, Lutumba P, de Vlas SJ, et al. Forecasting human African trypanosomiasis prevalences from population screening data using continuous time models. PLOS Computational Biology. 2016;12(9):1–23.

- 23. Davis CN, Rock KS, Mwamba Miaka E, Keeling MJ. Village-scale persistence and elimination of gambiense human African trypanosomiasis. PLOS Neglected Tropical Diseases. 2019;13(10):e0007838.
- 24. Keeling MJ, Ross JV. On methods for studying stochastic disease dynamics. Journal of the Royal Society Interface. 2008;5(19):171–181.
- 25. Aliee M, Rock KS, Keeling MJ. Estimating the distribution of time to extinction of infectious diseases in mean-field approaches. Journal of the Royal Society Interface. 2020;17(173):20200540.
- 26. Spencer SE. Accelerating adaptation in the adaptive Metropolis–Hastings random walk algorithm. Australian & New Zealand Journal of Statistics. 2021;63(3):468–484.
- 27. Andrieu C, Doucet A, Holenstein R. Particle markov chain monte carlo methods. Journal of the Royal Statistical Society: Series B (Statistical Methodology). 2010;72(3):269–342.
- 28. Simarro PP, Cecchi G, Jannin JG. The Atlas of human African trypanosomiasis: a contribution to global mapping of neglected tropical diseases. International Journal of Health Geographics. 2010;9:57.
- 29. Rock KS, Torr SJ, Lumbala C, Keeling MJ. Predicting the impact of intervention strategies for sleeping sickness in two high-endemicity health zones of the Democratic Republic of Congo. PLoS Neglected Tropical Diseases. 2017;11:e0005162.
- 30. Huang CI, Crump RE, Brown PE, Spencer SE, Miaka EM, Shampa C, et al. Identifying regions for enhanced control of gambiense sleeping sickness in the Democratic Republic of Congo. Nature communications. 2022;13(1):1–11.
- 31. Mpanya A, Hendrickx D, Vuna M, Kanyinda A, Lumbala C, Tshilombo V, et al. Should I get screened for sleeping sickness? A qualitative study in Kasai province, Democratic Republic of Congo. PLOS Neglected Tropical Diseases. 2012;6(1):e1467.
- 32. Haines LR. Examining the tsetse teneral phenomenon and permissiveness to trypanosome infection. Frontiers in cellular and infection microbiology. 2013;3:84.
- 33. OCHA Office for the Coordination of Humanitarian Affairs. Journees Nationales de Vaccination (JNV) Activities de vaccination supplementaire, RDC; Accessed May 2016. https://data.humdata.org/about/license/legacy_hrinfo.
- 34. The World Bank. Data:Democratic Republic of Congo; 2015. Available from: <https://data.worldbank.org/country/congo-dem-rep?view=chart>.
- 35. Rogers D. A general model for the African trypanosomiases. Parasitology. 1988;97(1):193–212.
- 36. Checchi F, Filipe JAN, Barrett MP, Chandramohan D. The natural progression of Gambiense sleeping sickness: What is the evidence? PLoS Neglected Tropical Diseases. 2008;2(12):e303.
- 37. Checchi F, Chappuis F, Karunakara U, Priotto G, Chandramohan D. Accuracy of Five Algorithms to Diagnose Gambiense Human African Trypanosomiasis. PLoS Neglected Tropical Diseases. 2011;5(7):e1233–15.
- 38. Davis S, Aksoy S, Galvani A. A global sensitivity analysis for African sleeping sickness. Parasitology. 2011;138(4):516–526.

- 39. Ravel S, Grébaut P, Cuisance D, Cuny G. Monitoring the developmental status of Trypanosoma brucei gambiense in the tsetse fly by means of PCR analysis of anal and saliva drops. Acta Tropica. 2003;88(2):161–165.
- 40. Clausen PH, Adeyemi I, Bauer B, Breloeer M, Salchow F, Staak C. Host preferences of tsetse (Diptera: Glossinidae) based on bloodmeal identifications. Medical and Veterinary Entomology. 1998;12(2):169–180.
- 41. Lutumba P, Robays J, Mia Bilenge CM, Mesu VKBK, Molisho D, Declercq J, et al. Trypanosomiasis control, Democratic Republic of Congo, 1993–2003. Emerging infectious diseases. 2005;11(9):1382.
- 42. Franco JR, Simarro PP, Diarra A, Ruiz-Postigo JA, Jannin JG. The journey towards elimination of gambiense human African trypanosomiasis: not far, nor easy. Parasitology. 2014;141(6):748–760.
- 43. Lejon V, Hasker E, Büscher P. Rapid diagnostic tests for human African trypanosomiasis. Revolutionizing Tropical Medicine: Point-of-Care Tests, New Imaging Technologies and Digital Health. 2019; p. 159–169.
- 44. Inocencio da Luz R, Phanzu DM, Kiabanzawoko ON, Miaka E, Verlé P, De Weggheleire A, et al. Feasibility of a dried blood spot strategy for serological screening and surveillance to monitor elimination of Human African Trypanosomiasis in the Democratic Republic of the Congo. PLoS Neglected Tropical Diseases. 2021;15(6):e0009407.
- 45. Casta˜no MS, Aliee M, Mwamba Miaka E, Keeling MJ, Chitnis N, Rock KS. Screening strategies for a sustainable endpoint for gambiense sleeping sickness. The Journal of Infectious Diseases. 2019; p. jiz588.
- 46. Schön TB, Svensson A, Murray L, Lindsten F. Probabilistic learning of nonlinear dynamical systems using sequential Monte Carlo. Mechanical systems and signal processing. 2018;104:866–883.
- 47. Funk S, Camacho A, Kucharski AJ, Eggo RM, Edmunds WJ. Real-time forecasting of infectious disease dynamics with a stochastic semi-mechanistic model. Epidemics. 2018;22:56–61.
- 48. Endo A, Van Leeuwen E, Baguelin M. Introduction to particle Markov-chain Monte Carlo for disease dynamics modellers. Epidemics. 2019;29:100363.
- 49. Griffin A, Jenkins PA, Roberts GO, Spencer SE. Simulation from quasi-stationary distributions on reducible state spaces. Advances in Applied Probability. 2017;49(3):960–980.
- 50. Douc R, Cappé O. Comparison of resampling schemes for particle filtering. In: Ispa 2005. proceedings of the 4th international symposium on image and signal processing and analysis, 2005. IEEE; 2005. p. 64–69.
- 51. Gelman A, Rubin DB, et al. Inference from iterative simulation using multiple sequences. Statistical science. 1992;7(4):457–472.
- 52. Plummer M, Best N, Cowles K, Vines K. CODA: Convergence Diagnosis and Output Analysis for MCMC. R News. 2006;6(1):7–11.
- 53. Funk S, Nishiura H, Heesterbeek H, Edmunds WJ, Checchi F. Identifying Transmission Cycles at the Human-Animal Interface: The Role of Animal Reservoirs in Maintaining Gambiense Human African Trypanosomiasis. PLOS Computational Biology. 2013;9(1):1–9. doi:10.1371/journal.pcbi.1002855.

- 54. Cecchi G, Paone M, Argilés Herrero R, Vreysen MJ, Mattioli RC. Developing a continental atlas of the distribution and trypanosomal infection of tsetse flies (Glossina species). Parasites $& \text{Vectors. } 2015;8(1):1-10.$
- 55. Büscher P, Bart JM, Boelaert M, Bucheton B, Cecchi G, Chitnis N, et al. Do cryptic reservoirs threaten gambiense-sleeping sickness elimination? Trends in Parasitology. 2018;34(3):197–207.
- 56. Aliee M, Keeling MJ, Rock KS. Modelling to explore the potential impact of asymptomatic human infections on transmission and dynamics of African sleeping sickness. PLoS computational biology. 2021;17(9):e1009367.
- 57. Lindner AK, Lejon V, Chappuis F, Seixas J, Kazumba L, Barrett MP, et al. New WHO guidelines for treatment of gambiense human African trypanosomiasis including fexinidazole: substantial changes for clinical practice. The Lancet Infectious Diseases. 2020;20(2):e38–e46.
- 58. Antillon M, Huang CI, Crump RE, Brown PE, Snijders R, Miaka EM, et al. Cost-effectiveness of sleeping sickness elimination campaigns in five settings of the Democratic Republic of Congo. Nature Communications. 2022;13(1):1051.